clinical trial · NCT07010263
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Akeso·phase3·recruiting·n = 560
Small Cell Lung CancerAK112Placebo
brief summary
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK112 to placebo as consolidation treatment for patients with limited stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy.
started
Jun 13, 2025
primary completion
Dec 31, 2028
completion
Jul 31, 2029
last updated
Mar 5, 2026
official title
A Multicenter, Randomized, Double-blind, Phase III Clinical Study of Comparing the Efficacy and Safety of AK112 (PD-1/VEGF Bispecific Antibody) Versus Placebo as Consolidation Treatment for Patients With Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol